Dr. Emad Shash discusses organizational and regulatory constraints for international clinical trials for rare cancers
23 May 2013
In an article appearing in ecancermedicalscience, the EORTC’s Emad Shash, Anastassia Negrouk, Sandrine Marreaud, Vassilis Golfinopoulos, Denis Lacombe and Francoise Meunier outline organizational and regulatory constraints for international clinical trials for rare cancers. In an accompanying interview, Dr. Shash offers further insight into this topic.
Related News
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
